NCT03287050终止2 期
FAST: Feasibility Trial of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- The Percentage of Subjects Who Receive 4 Doses of Pembrolizumab and at Least One Session of Treatment of SBRT
研究概览
简要总结
This is a feasibility trial of anti-PDL1/PD1 (pembrolizumab) and stereotactic body radiation therapy (SBRT) in patients with advanced, platinum-refractory urothelial carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have a histologic diagnosis of urothelial carcinoma
- •Subjects must have radiologic evidence of metastatic disease with measurable disease by RECIST 1.1 criteria other than the target lesion(s) for SBRT
- •Subjects must have at least 1 metastatic lesion previously not radiated that is amenable to SBRT per treating radiation oncologist.
- •Subjects must have had progression of disease within 12 months of platinum-containing chemotherapy (chemotherapy could have been given in the neoadjuvant, adjuvant or metastatic setting) for urothelial cancer
- •ECOG performance status of 0 to 2 (Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death.)
- •Absolute neutrophil count of ≥ 1000/mm3, platelet count ≥ 100,000/mm3, hemoglobin ≥ 8.0 g/dl; total bilirubin/ALT/AST < 2.5 x upper limit of normal (patients with known gilbert disease who have serum bilirubin ≤3x ULN may be enrolled); serum creatinine <3.0mg/dl or if elevated, a calculated estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73 m2
- •Subjects must have recovered to baseline or ≤ grade 1 CTCAE v 4.03 from toxicities related to any prior treatments unless AE(s) are clinically non-significant and/or stable on supportive therapy
- •Subjects must be ≥ 2 weeks from most recent systemic therapy or most recent radiation therapy
- •Women of childbearing potential must have a negative serum or urine pregnancy test within 28 days prior to registration.
- •Age ≥ 18 years
排除标准
- •Prior treatment with anti-PD-1/PD-L1 and anti-CTLA-4 is NOT allowed. Prior intravesical BCG (Bacillus Calmette-Guerin) therapy is allowed
- •Treatment with any investigational agent or on an interventional clinical trial within 30 days prior to registration.
- •No prior or concurrent malignancy is allowed except for: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, localized or locally advanced prostate cancer definitively treated without recurrence or with biochemical recurrence only, or any other cancer fully treated or from which the subject has been disease-free for at least 2 years.
- •Autoimmune diseases such as rheumatoid arthritis are NOT allowed. Vitiligo, mild psoriasis (topical therapy only) or hypothyroidism are allowed
- •Need for systemic corticosteroids >10mg prednisone daily or equivalent alternative steroid
- •Any history of organ allografts
- •Any history of HIV or hepatitis B infection
- •Known brain metastases
研究组 & 干预措施
Pembrolizumab + SBRT
Experimental
干预措施: Pembrolizumab (Drug)
Pembrolizumab + SBRT
Experimental
干预措施: SBRT (Radiation)
结局指标
主要结局
The Percentage of Subjects Who Receive 4 Doses of Pembrolizumab and at Least One Session of Treatment of SBRT
时间窗: 15 weeks
Feasibility will be determined by the percentage of subjects who receive 4 doses of pembrolizumab and at least one session of treatment of SBRT (Stereotactic Body Radiation Therapy) within 15 weeks from the first dose of pembrolizumab.
次要结局
- The Number of Grades 3-5 Drug Related Adverse Events (AEs)(30 days post last dose)
- Progression Free Survival (PFS) Time(24 months)
- The Percentage of Patients That Respond to Treatment(51 weeks (up to 17, 3 week doses))
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid TumorsSolid TumorNCT02608385University of Chicago117
招募中
2 期
Pembrolizumab and Radiotherapy for Patients With NK/T Cell LymphomaLymphoma, Extranodal NK-T-CellNCT04417166International Extranodal Lymphoma Study Group (IELSG)30
已完成
2 期
A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.MelanomaNCT02821182University Hospital, Ghent20
已完成
1 期
Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal TumoursRenal Cell CarcinomaNCT02855203Peter MacCallum Cancer Centre, Australia30
招募中
1 期
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent GlioblastomaGlioblastoma MultiformeNCT04977375Chirag G. Patil10